Latest Ratios: P/E Ratio -6.0x · EV/EBITDA N/A · ROE -26.1%. (2021–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $491M | $317M | $379M | — | — | — |
| Enterprise Value | $423M | $249M | $363M | — | — | — |
| P/E Ratio → | -6.05 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 1.39 | 1.21 | 1.91 | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | 100.0% | — | — |
| Operating Margin | — | — | — | -32.2% | — | — |
| Net Profit Margin | — | — | — | 45.4% | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -26.1% | -26.1% | -64.9% | — | -48.1% | -47.1% |
| ROA | -24.5% | -24.5% | -24.6% | 25.1% | -40.0% | -41.1% |
| ROIC | -27.1% | -27.1% | -26.1% | -16.2% | -33.6% | — |
| ROCE | -29.0% | -29.0% | -31.1% | -19.1% | -41.3% | -42.9% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.03 | — | 0.15 | 0.08 |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.26 | -0.08 | — | 0.01 | 0.00 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | 9.38 | — | — |
| Interest Coverage | — | — | — | 112.39 | -61.51 | -86.35 |
Net cash position: cash ($76M) exceeds total debt ($8M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 27.50 | 27.50 | 20.69 | 23.29 | 6.41 | 18.99 |
| Quick Ratio | 27.50 | 27.50 | 20.69 | 23.29 | 6.41 | 18.99 |
| Cash Ratio | 26.98 | 26.98 | 20.53 | 22.83 | 6.26 | 18.78 |
| Asset Turnover | — | — | — | 0.38 | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $28M | $26M | $25M | $25M | $25M |
Includes 30+ ratios · 5 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CTNM stock.
Contineum Therapeutics, Inc.'s current P/E ratio is -6.0x. This places it at the 50th percentile of its historical range.
Contineum Therapeutics, Inc.'s return on equity (ROE) is -26.1%. The historical average is -46.6%.
Based on historical data, Contineum Therapeutics, Inc. is trading at a P/E of -6.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Pre-revenue cash burn sustainability
Metrics are mathematically derived from official filings.
Valuation Anchored to Speculative Pipeline
Contineum's P/B ratio of 1.81, as reported in recent financial statements, is modest for a pre-revenue biotech, suggesting the market is pricing in minimal value for its clinical-stage assets relative to peers like ARQT (P/B 15.97) and KYMR (P/B 6.31).
The negative P/E and lack of EV/EBITDA multiples are expected for a company with no revenue or earnings, making traditional valuation metrics inapplicable. The P/B ratio becomes the primary anchor, and its level relative to peers indicates a more conservative market assessment of CTNM's asset base and pipeline potential. Investors must rely on risk-adjusted net asset value or probability-weighted pipeline models, as the current multiples offer little insight into growth expectations.
Liquidity Ratio Masks Critical Cash Depletion
The current ratio of 37.17 in 2026Q2, as per the company's balance sheet, appears exceptionally strong but is misleading, as it is driven by a cash position that has collapsed from $75.6M to $14.7M over six quarters, indicating a rapidly narrowing funding runway.
The identical current and quick ratios confirm the company holds virtually no inventory, which is typical for a pre-commercial biotech. However, the extreme ratio level is a function of minimal current liabilities, not robust operational liquidity. The critical trend is the 80% decline in cash, which, when paired with a quarterly operating loss of approximately $17M, suggests the company's apparent liquidity strength is a temporary artifact of its capital structure, not a sustainable buffer.
Minimal Leverage Amidst Equity Erosion
Contineum's debt-to-equity ratio of 0.03, as reported in its financial filings, indicates a near-zero reliance on debt financing, which is a prudent structure for a pre-revenue company but does not offset the fundamental risk of equity dilution from persistent cash burn.
The consistently low D/E ratio and the absence of interest coverage data suggest the company has avoided traditional debt, likely relying on equity issuances and grants. This minimizes fixed financial obligations but places the entire burden of funding operations on shareholders. The primary risk is not debt service but the continuous need for external capital, which may lead to significant dilution as the cash runway shortens.
Negative Returns Reflecting Pure R&D Burn
Return on Invested Capital (ROIC) has been consistently negative, averaging -6.8% over the last ten quarters, as calculated from reported figures, which is expected for a clinical-stage biotech but underscores that all capital deployed is currently consumed by research without generating returns.
The negative ROIC, ROE, and ROA metrics are a direct mathematical consequence of the company's pre-revenue status and operating losses. The singular positive ROIC of 36.1% in 2024Q4 is an anomaly driven by a one-time gain, not operational performance. The trend shows no improvement in capital efficiency, confirming that the company is in a pure investment phase where the goal is pipeline advancement, not near-term returns on capital.
The Misleading Strength of the Current Ratio
The current ratio is the most commonly misapplied metric to Contineum's business model, as its extreme value of 37.17 obscures the urgent reality of a cash position that has fallen to $14.7M against a quarterly burn rate of approximately $17M.
For a pre-revenue, cash-burning biotech, the current ratio is a poor indicator of financial health because it is inflated by a large cash balance relative to minimal payables, while ignoring the trajectory of that cash. A more appropriate metric is the cash runway, calculated by dividing the remaining cash by the average quarterly cash burn from operations. This adjustment reveals the company's true liquidity constraint and the imminent need for financing, which the headline ratio completely masks.